Literature DB >> 30223401

Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.

Kristin J Krosschell1,2, Michael Bosch3, Leslie Nelson4, Tina Duong5, Linda P Lowes6, Lindsay N Alfano6, Danielle Benjamin7, Terri B Carry8, Ginger Devine9, Carolyn Kelley8, Rebecca Gadekan10, Elizabeth C Malkus11, Amy Pasternak12,13, Stephanie Provance-Orr14, Lynne Roemeiser-Logan15, Alina Nicorici16, Donata Trussell17, Sally Dunaway Young18, Jennifer R Fetterman15, Jacqueline Montes18, Penny J Powers9, Rebecca Quinones19, Janet Quigley12,13, Christopher S Coffey3, Jon W Yankey3, Amy Bartlett20, John T Kissel20, Stephen J Kolb20,21.   

Abstract

BACKGROUND: The NeuroNEXT SMA Infant Biomarker Study, a two year, longitudinal, multi-center study of infants with SMA type 1 and healthy infants, presented a unique opportunity to assess multi-site rater reliability on three infant motor function tests (MFTs) commonly used to assess infants with SMA type 1.
OBJECTIVE: To determine the effect of prospective MFT rater training and the effect of rater experience on inter-rater and intra-rater reliability for the Test of Infant Motor Performance Screening Items (TIMPSI), the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) and the Alberta Infant Motor Scale (AIMS).
METHODS: Training was conducted utilizing a novel set of motor function test (MFT) videos to optimize accurate MFT administration and reliability for the study duration. Inter- and intra-rater reliability of scoring for the TIMPSI and inter-rater reliability of scoring for the CHOP INTEND and the AIMS was assessed using intraclass correlation coefficients (ICC). Effect of rater experience on reliability was examined using ICC. Agreement with 'expert' consensus scores was examined using Pearson's correlation coefficients.
RESULTS: Inter-rater reliability on all MFTs was good to excellent. Intra-rater reliability for the primary MFT, the TIMPSI, was excellent for the study duration. Agreement with 'expert' consensus was within predetermined limits (≥85%) after training. Evaluator experience with SMA and MFTs did not affect reliability.
CONCLUSIONS: Reliability of scores across evaluators was demonstrated for all three study MFTs and scores were reproducible on repeated administration. Evaluator experience had no effect on reliability.

Entities:  

Keywords:  AIMS; CHOP-INTEND; NeuroNEXT; Spinal muscular atrophy; TIMPSI; clinical evaluator; motor function testing; neuromuscular diseases; outcome measures; reliability

Mesh:

Substances:

Year:  2018        PMID: 30223401      PMCID: PMC8112280          DOI: 10.3233/JND-180327

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  35 in total

1.  The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation.

Authors:  Marion Main; Harvey Kairon; Eugenio Mercuri; Francesco Muntoni
Journal:  Eur J Paediatr Neurol       Date:  2003       Impact factor: 3.140

Review 2.  Intraclass correlations: uses in assessing rater reliability.

Authors:  P E Shrout; J L Fleiss
Journal:  Psychol Bull       Date:  1979-03       Impact factor: 17.737

3.  Central institutional review board review for an academic trial network.

Authors:  Petra Kaufmann; P Pearl O'Rourke
Journal:  Acad Med       Date:  2015-03       Impact factor: 6.893

Review 4.  Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.

Authors:  Eugenio Mercuri; Richard S Finkel; Francesco Muntoni; Brunhilde Wirth; Jacqueline Montes; Marion Main; Elena S Mazzone; Michael Vitale; Brian Snyder; Susana Quijano-Roy; Enrico Bertini; Rebecca Hurst Davis; Oscar H Meyer; Anita K Simonds; Mary K Schroth; Robert J Graham; Janbernd Kirschner; Susan T Iannaccone; Thomas O Crawford; Simon Woods; Ying Qian; Thomas Sejersen
Journal:  Neuromuscul Disord       Date:  2017-11-23       Impact factor: 4.296

5.  Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study.

Authors:  Kathie M Bishop; Jacqueline Montes; Richard S Finkel
Journal:  Muscle Nerve       Date:  2017-06-14       Impact factor: 3.217

6.  Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy.

Authors:  Kristin J Krosschell; Charles B Scott; Jo Anne Maczulski; Aga J Lewelt; Sandra P Reyna; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2011-06-22       Impact factor: 3.217

7.  The test of infant motor performance: reliability in spinal muscular atrophy type I.

Authors:  Richard S Finkel; Linda S Hynan; Allan M Glanzman; Hollis Owens; Leslie Nelson; Stephanie R Cone; Suzann K Campbell; Susan T Iannaccone
Journal:  Pediatr Phys Ther       Date:  2008       Impact factor: 3.049

8.  Construction and validation of the Alberta Infant Motor Scale (AIMS).

Authors:  M C Piper; L E Pinnell; J Darrah; T Maguire; P J Byrne
Journal:  Can J Public Health       Date:  1992 Jul-Aug

9.  The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.

Authors:  A M Glanzman; E Mazzone; M Main; M Pelliccioni; J Wood; K J Swoboda; C Scott; M Pane; S Messina; E Bertini; E Mercuri; R S Finkel
Journal:  Neuromuscul Disord       Date:  2010-01-13       Impact factor: 4.296

10.  Assessing upper limb function in nonambulant SMA patients: development of a new module.

Authors:  Elena Mazzone; Flaviana Bianco; Diego Martinelli; Allan M Glanzman; Sonia Messina; Roberto De Sanctis; Marion Main; Michelle Eagle; Julaine Florence; Kristin Krosschell; Gessica Vasco; Marco Pelliccioni; Marilena Lombardo; Marika Pane; Richard Finkel; Francesco Muntoni; Enrico Bertini; Eugenio Mercuri
Journal:  Neuromuscul Disord       Date:  2011-03-21       Impact factor: 4.296

View more
  2 in total

Review 1.  Molecular Biomarkers for Spinal Muscular Atrophy: A Systematic Review.

Authors:  Angela Navarrete-Opazo; Sheldon Garrison; Mindy Waite
Journal:  Neurol Clin Pract       Date:  2021-08

2.  Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.

Authors:  Merit Cudkowicz; Marianne K Chase; Christopher S Coffey; Dixie J Ecklund; Brenda J Thornell; Codrin Lungu; Katy Mahoney; Laurie Gutmann; Jeremy M Shefner; Kevin J Staley; Michael Bosch; Eric Foster; Jeffrey D Long; Emine O Bayman; James Torner; Jon Yankey; Richard Peters; Trevis Huff; Robin A Conwit; Shlomo Shinnar; Donna Patch; Basil T Darras; Audrey Ellis; Roger J Packer; Karen S Marder; Claudia A Chiriboga; Claire Henchcliffe; Joyce Ann Moran; Blagovest Nikolov; Stewart A Factor; Carole Seeley; Steven M Greenberg; Anthony A Amato; Sara DeGregorio; Tanya Simuni; Tina Ward; John T Kissel; Stephen J Kolb; Amy Bartlett; Joseph F Quinn; Kellie Keith; Steven R Levine; Nadege Gilles; Patricia K Coyle; Jessica Lamb; Gil I Wolfe; Annemarie Crumlish; Luis Mejico; Muhammad Maaz Iqbal; James D Bowen; Caryl Tongco; Louis B Nabors; Khurram Bashir; Melanie Benge; Craig M McDonald; Erik K Henricson; Björn Oskarsson; Bruce H Dobkin; Catherine Canamar; Tracy A Glauser; Daniel Woo; Angela Molloy; Peggy Clark; Timothy L Vollmer; Alexander J Stein; Richard J Barohn; Mazen M Dimachkie; Jean-Baptiste Le Pichon; Michael G Benatar; Julie Steele; Lawrence Wechsler; Paula R Clemens; Christine Amity; Robert G Holloway; Christine Annis; Mark P Goldberg; Mariam Andersen; Susan T Iannaccone; A Gordon Smith; J Robinson Singleton; Mariana Doudova; E Clarke Haley; Mark S Quigg; Stephanie Lowenhaupt; Beth A Malow; Karen Adkins; David B Clifford; Mengesha A Teshome; Noreen Connolly
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.